Table 4

Characteristics of NPC patients in 3 different risk (ΔCONUT-EBV DNA score) groups

CharacteristicsLRG N = 217 (%)MRG N = 170 (%)HRG N = 46 (%)PBonferroni holm corrected P
LRG vs. MRGLRG vs. HRGMRG vs. HGRLRG vs. MRGLRG vs. HRGMRG vs. HGR
Age (years)0.0330.1841.0000.0990.5521.000
 ≤46127 (58.5)81 (47.6)22 (47.8)
 >4690 (41.5)89 (52.4)24 (52.2)
Gender0.0510.0420.2340.1530.1260.702
 Female65 (30.0)42 (24.7)7 (15.2)
 Male152 (70.0)128 (75.3)39 (84.8)
UICC T stage0.2480.7020.1620.7441.0000.486
 112 (5.5)4 (2.4)4 (8.7)
 242 (19.4)28 (16.5)10 (21.7)
 3127 (58.5)101 (59.4)23 (50.0)
 436 (16.8)37 (21.8)9 (19.6)
UICC N stage0.001<0.0010.3340.003<0.0011.000
 038 (17.5)13 (7.6)1 (2.2)
 1101 (46.5)65 (38.2)17 (37.0)
 267 (30.9)75 (44.1)20 (43.5)
 311 (5.1)17 (10.0)8 (17.4)
Clinical stage0.0020.1190.2630.0060.3570.789
 II26 (12.0)6 (3.5)4 (8.7)
 III146 (67.3)111 (65.3)26 (56.5)
 IV45 (20.7)53 (31.2)16 (34.8)
WHO histology1.0000.7040.6791.0001.0001.000
 II7 (3.2)6 (3.5)2 (4.3)
 III210 (96.8)164 (96.5)44 (95.7)
Smoking status0.4400.1270.4511.0000.3811.000
 Non-smoker143 (65.9)102 (60.0)23 (50.0)
 Ex-smoker13 (6.0)10 (5.9)4 (8.7)
 Current smoker61 (28.1)58 (34.1)19 (41.3)
VCA IgA0.0230.4120.5540.0691.0001.000
 ≤8070 (32.3)37 (21.8)12 (26.1)
 >80147 (67.7)133 (78.2)34 (73.9)
EA IgA0.0120.9400.1310.0361.0000.393
 ≤20145 (66.8)92 (54.1)31 (67.4)
 >2072 (33.2)78 (45.9)15 (32.6)

NPC, nasopharyngeal carcinoma; LRG, low-risk group = ΔCONUT-EBV DNA Score 1 (EBV DNA ≤ 2,110 copies/mL); MRG, middle-risk group = ΔCONUT-EBV DNA Score 2 (both ΔCONUT Score ≤ 3 and EBV DNA > 2,110 copies/mL); HRG, high-risk group = ΔCONUT-EBV DNA Score 3 (both ΔCONUT Score > 3 and EBV DNA > 2,110 copies/mL); CONUT, controlling nutritional status score; N stage, node stage; T stage, tumor stage; UICC, Union for International Cancer Control; WHO, World Health Organization; EBV DNA, Epstein-Barr virus deoxyribonucleic acid; VCA, viral capsid antigen; EA, early antigen; IgA, immunoglobulin a.